#IntensityTherapeutics' CEO, Lew Bender, joins Pharma's Almanac's December roundtable to discuss the rise of #GLP1 therapies and their impact on the pharmaceutical landscape. Read the full roundtable: bit.ly/3YkGNfT $INTS

🔴 ÚLTIMA HORA | La Guardia Civil encuentra calcinada la caja con los votos por correo robados en Extremadura y Correos confirma que los afectados volverán a votar cadenaser.com/nacional/2025/…

$INTS can Intensity become serious 2nd contender for $NVO for their delivery compound similar to $MTSE Metsera Rybelsus acquired by $PFE? 'Intensity uses a similar molecular delivery technology to that of Rybelsus's; yet, while we have discovered compounds that could create

$INTS Interesting documents docs.publicnow.com/viewDoc?hash_p… docs.publicnow.com/viewDoc?hash_p…

$INTS Top 5 Best Potential Partners/Acquirers for INTS DfuseRx is an oncology-local-delivery platform, so the natural acquirers are: $BMY $MRK $RHHBY $AZN $LLY Companies with large chemotherapy franchises, Companies with intratumoral or immunotherapy synergy gaps, Companies with

$INTS #1. Bristol Myers Squibb (BMS) — Most Likely $BMY $MRK $RHHBY $AZN $LLY

$INTS #2. Merck (MRK) — Highly Likely $BMY $MRK $RHHBY $AZN $LLY

$INTS #3. Roche / Genentech — High $BMY $MRK $RHHBY $AZN $LLY

$INTS #4. AstraZeneca — High $BMY $MRK $RHHBY $AZN $LLY

$INTS #5. Eli Lilly (LLY) — Medium $BMY $MRK $RHHBY $AZN $LLY

$INTS MOST LIKELY STRATEGIC SCENARIOS Scenario A — Partner-funded approval The most realistic near-term scenario: ✔ BMS or Merck funds: -Phase 3 completion (sarcoma) -TNBC expansion -Milestone payments -Rights-of-first-negotiation -Co-commercialization → Leads to takeover

$INTS MOST LIKELY STRATEGIC SCENARIOS Scenario B — Early Buyout After Strong Data If: -INVINCIBLE-3 Phase 3 shows clear survival benefit -TNBC presurgical trial continues showing strong tumor necrosis -Abscopal immune responses appear reproducible -Low systemic toxicity is

The pace of progress at Childress is accelerating! Just months after breaking ground, Horizon 1 electrical and mechanical works are well underway, Horizon 2 data halls are rising, Horizon 3-4 civils have commenced, and more than 1,200 workers are active on site bringing this

Rittenhouse Research Daniel Roberts There are 3 major flaws in your $IREN model: 1) Your CAPEX sequencing is off. With the initial 5 year deal, you are assuming that 100% of CAPEX occurs in year 0, with a 1 year delay until revenues kick in. In reality, CAPEX cash outflows (especially GPUs) happen in phases and

The Epstein files on the DOJ website allow you to highlight the redacted text, copy it, and paste it into another document, which reveals what was hidden. You can also press Ctrl+F and search for “Trump ” (with a space) to see his name appear more than 600 times. #OpDeathEaters

🚨 Impressive investigation by Compute Capital suggests that $IREN may sign a deal with xAI for Horizon 5 - 10. Worth following!

$INTS Forgot the essential here… high probability of partnership in Q1 with either $BMY or $MRK with onetime lump sum (~30M$+) therefore eliminating need to use the 30M equity financing and at same becoming Nasdaq compliant with the HUGE stock repricing (3-5$) $LLY $RHHBY $AZN

Gracias por su trabajo.